Our internationally recognised publications give you access to the expertise of hundreds of the world’s leading scientists, experts and researchers.

Our unrivalled collection of publications spans evidence-based clinical knowledge, research and regulatory information. The extensive breadth of content on MedicinesComplete supports your decision making, from research to the point of care and provides you with the world’s most trusted resources.

We’re excited to announce the launch of two new resources: Martindale’s ADR Checker, a quick and easy tool to support you when managing patients with adverse drug reactions, and the Palliative Care Formulary, the expert source of drug information in palliative and hospice care.

Subscribe Publication Updates

Publication Updates

10 Sep
British National Formulary logo
BNF September 2019 Update

This update contains 11 significant changes, 1 dose change and 3 new preparations.

Significant Changes: 

  • Blinatumomab for treating acute lymphoblastic leukaemia in remission with minimal residual disease activity [NICE guidance].
  • Febuxostat (Adenuric®): increased risk of cardiovascular death and all-cause mortality in clinical trial in patients with a history of major cardiovascular disease [MHRA/CHM advice].
  • Fluocinolone acetonide intravitreal implant for treating recurrent non-infectious uveitis [NICE guidance].
  • Letermovir for preventing cytomegalovirus disease after a stem cell transplant [NICE guidance].
  • Migraine: updated guidance on management.
  • Nusinersen for treating spinal muscular atrophy [NICE guidance].
  • Rivaroxaban (Xarelto®): reminder that 15 mg and 20 mg tablets should be taken with food [MHRA/CHM advice].
  • Stroke: updated guidance on management.
  • Tocilizumab (RoActemra®): rare risk of serious liver injury including cases requiring transplantation [MHRA/CHM advice].
  • Typhoid vaccine: updated guidance in line with Public Health England recommendations.
  • Urinary-tract infections: updated guidance on management.

 

Dose Changes:

  • Typhoid vaccine [booster dose added].

 

New Preparations: Imvaggis® pessary [estriol], Ledaga® gel [chlormethine], Renoxitin® [cefoxitin].

 

For further details on changes in the BNF click on http://www.medicinescomplete.com/mc/bnf/current/PHP107699-changes.htm

 

10 Sep
British National Formulary for Children logo
BNFC September 2019 Update

This update contains 4 significant changes, 1 dose change and 1 new preparation.

Significant Changes: 

  • Nusinersen for treating spinal muscular atrophy [NICE guidance].
  • Tocilizumab (RoActemra®): rare risk of serious liver injury including cases requiring transplantation [MHRA/CHM advice].
  • Typhoid vaccine: updated guidance in line with Public Health England recommendations.
  • Urinary-tract infections: updated guidance on management.     

Dose Changes:

  • Typhoid vaccine [booster dose added].           

New Preparations: Renoxitin® [cefoxitin].

For further details on changes in the BNFC click on https://www.medicinescomplete.com/#/content/bnfc/PHP107699?hspl=changes

 

10 Sep
Stockley's Interactions Checker_logo
Stockley’s Interaction Checker September 2019 Update

New and updated interactions now available

For September, 142 new interactions have been added, and 30 existing interactions have been updated.

10 Sep
Martindale logo
Martindale September 2019 Update

This update contains 10 new monographs and 9 existing monographs have been updated. Preparations have been updated for 4 countries.

New monographs:

  • Benzhydrocodone: an opioid analgesic, is a prodrug of hydrocodone that is given with paracetamol in the short-term treatment of acute pain.
  • Cemiplimab: is a human immunoglobulin G4 monoclonal antibody and immune checkpoint inhibitor that binds to PD-1. It is used in the treatment of metastatic or locally advanced cutaneous squamous cell carcinoma.
  • Evocalcet: is a calcimimetic agent used in the treatment of secondary hyperparathyroidism in patients with chronic kidney disease on haemodialysis.
  • Fexinidazole: is a 5-nitroimidazole derivative with antiprotozoal activity used in the treatment of African trypanosomiasis due to infection with Trypanosoma brucei gambiense (Gambian or West African sleeping sickness). It is also under investigation for the treatment of American trypanosomiasis (Chagas’ disease).
  • Gilteritinib: is a multikinase inhibitor used for the treatment of acute myeloid leukaemia with an FMS-like tyrosine kinase 3 (FLT3) mutation.
  • Pegvaliase: is a recombinant, pegylated form of the enzyme phenylalanine ammonia lyase (PAL). It is used as an adjunct to the dietary restriction of phenylalanine in adults with phenylketonuria.
  • Pemafibrate: a fibric acid derivative, is a lipid regulating drug used in the treatment of hyperlipidaemias.
  • Risankizumab: is a human monoclonal antibody that binds to interleukin-23 and is used in the treatment of plaque psoriasis. It is also under investigation for the treatment of Crohn’s disease and ulcerative colitis.
  • Siponimod: is an immunomodulator used in the treatment of patients with relapsing forms of multiple sclerosis, including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease.
  • Solriamfetol: is a central stimulant that selectively inhibits dopamine and noradrenaline reuptake. It is used in the treatment of excessive daytime sleepiness associated with narcolepsy or obstructive sleep apnoea. Solriamfetol is also under investigation for improving sleep in patients with glioma.

Notable revisions: 

  • Abiraterone acetate: can also be used to treat newly-diagnosed, metastatic hormone-sensitive prostate cancer, in combination with androgen deprivation therapy.
  • Atezolizumab: can now be used to treat metastatic non-small cell lung cancer, advanced or metastatic breast cancer, and extensive-stage small cell lung cancer.
  • Caplacizumab: is a monoclonal antibody that binds to von Willebrand factor that is used in the treatment of acquired thrombotic thrombocytopenic purpura.
  • Ciclosporin eye drops: can be used to treat vernal keratoconjunctivitis in children aged 4 years and over, and in adolescents.
  • Edaravone: is also used in the treatment of amyotrophic lateral sclerosis.
  • Esketamine: is licensed in the UK for use in general anaesthesia, as a supplement to regional and local anaesthesia, and to provide analgesia in emergency care.
  • Fingolimod: is licensed for the treatment of relapsing-remitting MS in children aged 10 years and older. Adverse effects and precautions section also updated.
  • Flupirtine: EMA has recommended the withdrawal of flupirtine from the market in Europe because of continued reports of severe hepatotoxicity
  • Mexiletine: can also be used in adults with myotonia in non-dystrophic myotonic disorders.

Updated names, synonyms and codes; official standards; official preparations:

  • BP 2019
  • USP 42/USNF 37
  • ATC codes

Proprietary Preparations and Manufacturers updated for the following countries and regions:

  • Canada
  • Germany
  • USA
  • UK

† Countries updated on an ongoing basis

10 Sep
AHFS Drug Information logo
AHFS September 2019 Update

This update contains 5 new monographs and 72 revised monographs.

New monographs: Solriamfetol; Polatuzumab Vedotin; Amifampridine; Bremelanotide; Selinexor.

Revised monographs: Gefitinib; Erlotinib; Nabilone; Ceftaroline; Afatinib; Osimertinib; Bezlotoxumab; Becaplermin; Erenumab-aooe; Dacomitinib; Talazoparib; Amifampridine; Ketamine; Doxycycline; Tetracycline; Minocycline; Demeclocycline; sulfADIAZINE; sulfaSALAzine; Sodium Nitroprusside; Prazosin; Erythromycin Ethylsuccinate; Erythromycin; Menotropins; Tobramycin; Amikacin; Neomycin; Gentamicin; Streptomycin; Cefaclor; Cefadroxil; ceFAZolin; Cephalexin; Cefotaxime; Erythromycin Lactobionate; Erythromycin Stearate; Furosemide; Insulins General Statement; dilTIAZem; Cefuroxime; Bumetanide; Amoxicillin; Ampicillin; Penicillin G Benzathine; Penicillin G Potassium, Penicillin G Sodium; Penicillin G Procaine; Penicillin V; Dicloxacillin; Nafcillin; Oxacillin; Amoxicillin/Clavulanate; cefTRIAXone; cefTAZidime; Digoxin Immune Fab; Enalapril; Buprenorphine; Cefixime; Clarithromycin; Benazepril; amLODIPine; Lisinopril; Ampicillin/Sulbactam; Terazosin; Isradipine; Piperacillin and Tazobactam; niCARdipine; Azithromycin; Cefdinir; Cefepime; Cefprozil; Cefprozil; Ceftibuten; Cefpodoxime

10 Sep
Palliative Care Formulary September 2019 Update

This update contains 2 new monographs. 

The following monographs have been fully revised: Ascorbic acid; Abbreviations.

View more